Apellis Pharmaceuticals, Inc. (APLS) Presents at Baird Global Healthcare Conference

Company Overview - Apellis is focused on the complement pathways, specifically on complement factor C3, which allows for broad control of the complement pathway regardless of activation source [2] - The company is recognized as a global leader in this field and currently has three approved products on the market [2] Product Approval and Impact - The initial approval for EMPAVELI occurred in 2021 for the treatment of paroxysmal nocturnal hemoglobinuria, a blood-based disease caused by mutations that lead to the destruction of red blood cells by the complement pathway [3] - EMPAVELI has been described as a life-changing option for patients suffering from this condition [3]